A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)

Clinical trial NCT02259114 · COMPLETED

Trial details

NCT number: NCT02259114
Sponsor: Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

NUT Midline Carcinoma Triple Negative Breast Cancer Non-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation Castrate-resistant Prostate Cancer CRPC Pancreatic Ductal Adenocarcinoma

Start date: 2014-10-23
Primary completion: 2017-03-03
Enrollment: 47

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.